gemcitabine has been researched along with dinaciclib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bhagwat, B; Davis, N; Dwyer, MP; Gu, D; Guzi, TJ; Hsieh, Y; Labroli, M; Lee, S; Liu, M; Parry, D; Paruch, K; Penaflor, E; Seghezzi, W; Shanahan, F; Taricani, L; Wang, W; Wiswell, D | 1 |
| Alvarez, H; Bannerji, R; Bisht, S; Brossart, P; Dadon, T; Feldmann, G; Fendrich, V; Garrido-Laguna, I; Hidalgo, M; Karikari, C; Maitra, A; Matsui, W; Mishra, A; Nelkin, BD; Ottenhof, NA; Rajeshkumar, NV; Rasheed, Z | 1 |
| Bezrookove, V; Dar, AA; de Semir, D; Ice, RJ; Kashani-Sabet, M; McAllister, S; Nosrati, M; Osorio, R; Proetsch-Gugerbauer, H; Saqub, H; Soroceanu, L; Vaquero, EM | 1 |
3 other study(ies) available for gemcitabine and dinaciclib
| Article | Year |
|---|---|
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Replication; Drug Screening Assays, Antitumor; Gemcitabine; Histones; Humans; Immunoblotting; Indolizines; Mice; Mice, Nude; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyridinium Compounds; Pyrimidines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Indolizines; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Pyridinium Compounds; ral GTP-Binding Proteins; Receptors, Notch; Retinoblastoma Protein; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Topics: Animals; Apoptosis; bcl-X Protein; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase 9; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Histones; Humans; Indolizines; Inhibitory Concentration 50; Ki-67 Antigen; Male; Mice; Mice, Inbred NOD; Proto-Oncogene Proteins c-bcl-2; Pyridinium Compounds; Xenograft Model Antitumor Assays | 2020 |